- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Oxygen-enhanced MRI detects hypoxia within tumours
10 December 2015 • Author: Victoria White
Scientists have developed a new imaging test that could enable doctors to identify more dangerous tumours before they spread and tailor treatment accordingly.
Teams at The University of Manchester and The Institute of Cancer Research, London (ICR) describe detailed development of magnetic resonance imaging (MRI) technology to map areas of oxygen deprivation within tumours. Hypoxia stimulates the growth of blood vessels within tumours, which in turn can fuel the spread of cancer cells to other parts of the body.
The new study could also lead to more effective radiotherapy planning to boost the doses of X-rays delivered to dangerous, hypoxic areas within tumours, and new ways of monitoring whether radiotherapy or some drugs are working.
Researchers used oxygen-enhanced MRI to produce maps of hypoxia within tumours grown by implanting cancer cells into mice. The technology is now being further developed through clinical studies of cancer patients.
Oxygen-enhanced MRI works by monitoring alterations in image intensity caused by changes in the concentration of dissolved oxygen in blood plasma and tissue fluid, during inhalation of pure oxygen gas. Some tissues take up the extra oxygen more rapidly than others, which show as more intensely changing regions under the MRI scan.
The researchers predicted that images of hypoxic tumour areas would change intensity less dramatically than better oxygenated areas.
Oxygen-enhanced MRI could help monitor treatment response
They followed a several-step process to prove their MRI technique worked at detecting areas of hypoxia, beginning with the imaging of tumours grown from a cell line of kidney cancer cells known to lead to highly hypoxic tumours.They then imaged a slower-growing kidney tumour type and tumours grown from a line of bowel cancer cells, to show their technique also worked for less hypoxic tumours. They cross-referenced their images against samples from the tumours viewed under the microscope to confirm their findings from the scans.
Study co-leader Dr James O’Connor, Group Leader at The University of Manchester, said: “There is currently no validated, affordable and widely available clinical imaging technique that can rapidly assess the distribution of tumour hypoxia. Our findings from studies in mice are already being translated for use on conventional clinical MRI scanners. Ultimately we hope that oxygen-enhanced MRI will not only be used to identify the most dangerous tumours, but to assist radiotherapy treatment planning and for monitoring treatment response.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics